SILENCE THERAPEUTICS PLC SPON ADS EACH REP 3 ORD SHS SLN 深 沪
等待开盘 08-02 09:30:00 美东时间
6.17
+0.010
+0.16%
华盛通- 最 高6.28
- 今 开6.09
- 成交量 6.23万股
- 最 低 6.07
- 昨 收 6.16
- 总市值 2.91亿
- 52周最高 20.48
- 市盈率 静 --
- 换手率 0.13%
- 52周最低 1.97
- 委 比 -87.77%
- 总股本 4723.03万
- 历史最高 35.00
- 量 比 0.92
- 振 幅 3.41%
- 历史最低 1.97
- 每 手 1
- 风险率 5.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Silence Therapeutics Passes Key Resolutions at AGM
Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On June 26, 2025...
06-27 19:29
美股大行评级 | 潜在涨幅290.69%！乌龙制药获丰业银行升目标价至47美元，维持"跑赢大市"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140565699993591809.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 丰业银行：维持乌龙制药(URGN)"跑赢大市"评级，目标价从23美元升至47美元</p> <p>• Guggenheim：维持ADC Therapeutics(ADCT)"买入"评级，目标价从7美元升至10美元</p>
06-16 08:40
Silence Therapeutics Presents Additional Data Showcasing SANRECO Phase 1 Study Of Divesiran In Patients With PV At EHA 2025 Annual Meeting
Updated Phase 1 Data Presented at EHA 2025 Annual Meeting Reinforce Safety Profile, Efficacy Data and Dosing Convenience of DivesiranCompany Also Announces SANRECO Phase 2 Study Has Exceeded 50% Enrollment - On-track for
06-13 04:02
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers CNS Pharma (NASDAQ:CNSP) shares rose 90.1% to $2.3 during Tuesday's pr...
05-13 20:10
美股大行评级 | 潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
潜在涨幅754.7%！HC Wainwright & Co.：Alector获机构升目标价至10美元，维持"买入"评级
05-10 10:00
Chardan Capital Maintains Buy on Silence Therapeutics, Lowers Price Target to $35
Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:SLN) with a Buy and lowers the price target from $55 to $35.
05-09 18:45
Silence Therapeutics Q1 EPS $(0.20) Down From $(0.05) YoY, Sales $142.00K Down From $15.73M YoY
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.20) per share. This is a 300 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $142.00 thousand in
05-08 20:18
美股大行评级 | 美银证券：维持AerCap Holdings"买入"评级，目标价从105美元升至125美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1105190809351499777.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• RBC Capital：维持Canadian Natural Res(CNQ)"跑赢大市"评级，目标价从62美元升至63美元</p> <p>• 摩根大通：维持Carvana(CVNA)"超配"评级，目标价从350美元升至3
03-10 10:29
美股大行评级 | 富国银行：维持艾伯维"超配"评级，目标价从210美元升至240美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持AnaptysBio(ANAB)"超配"评级，目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20
美股大行评级 | 美银证券：维持艾伯维"中性"评级，目标价从200美元升至223美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1103964892578983937.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通：维持Syndax制药(SNDX)"超配"评级，目标价从35美元升至39美元</p> <p>• 摩根大通：维持Apellis Pharmaceuticals(APLS)"超配"评级，目标价从50美元升至54美元</
03-05 09:55
